<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02681263</url>
  </required_header>
  <id_info>
    <org_study_id>38RC15.213</org_study_id>
    <secondary_id>2015-004178-14</secondary_id>
    <nct_id>NCT02681263</nct_id>
  </id_info>
  <brief_title>Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae</brief_title>
  <acronym>TEMO-ESBL</acronym>
  <official_title>Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French National Network of Clinical Research in Infectious Diseases (RENARCI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims at demonstrating the efficacy of temocillin in the treatment of UTI&#xD;
      requiring parenteral therapy due to a confirmed ESBL producing or AmpC hyperproducing&#xD;
      Enterobacteriaceae, resistant to quinolones and Bactrim® in France. In addition, this study&#xD;
      will describe and support the use of high dose (6g/day) of temocillin which could be of&#xD;
      interest for the treatment urinary tract infection due to multi-resistant bacteria having&#xD;
      high MIC (up to 32 mg/L). The investigators will also evaluate the tolerance of the drug by&#xD;
      monitoring the adverse event and the incidence of eventual Clostridium difficile associated&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiological efficacy at Test of Cure in patients microbiologically evaluable</measure>
    <time_frame>7 days post end of Temocillin Treatment</time_frame>
    <description>The microbiological efficacy will be assessed by quantitative urine culture and defined as follows:&#xD;
Eradication : &lt; 10^3 CFU/mL of the baseline pathogen&#xD;
Persistence : ≥ 10^3 CFU/ml of the baseline pathogen&#xD;
Superinfection : ≥ 10^5 CFU/ml of another uropathogen during therapy&#xD;
New infection : ≥ 10^5 CFU/ml of another uropathogen after therapy&#xD;
Relapse : eradication at TOC but ≥ 10^3 CFU/mL of the baseline pathogen at FU Overall microbiological response will be determined as &quot;unfavorable&quot; if persistence or superinfection or new infection or relapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy in clinical evaluable group</measure>
    <time_frame>3 weeks for end of Temocillin Treatment</time_frame>
    <description>Each patient's response will be categorized as cure (resolution of all clinical symptoms), improvement (normalization of body temperature but persistence of either urinary syndrome or flank pain) or failure (persistence of baseline clinical symptoms or emergence of new symptoms related to UTI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological efficacy</measure>
    <time_frame>3 weeks for end of Temocillin Treatment</time_frame>
    <description>The microbiological efficacy will be assessed by quantitative urine culture and defined as follows:&#xD;
Eradication : &lt; 10^3 CFU/mL of the baseline pathogen&#xD;
Persistence : ≥ 10^3 CFU/ml of the baseline pathogen&#xD;
Superinfection : ≥ 10^5 CFU/ml of another uropathogen during therapy&#xD;
New infection : ≥ 10^5 CFU/ml of another uropathogen after therapy&#xD;
Relapse : eradication at TOC but ≥ 10^3 CFU/mL of the baseline pathogen at FU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of resistance to temocillin during treatment</measure>
    <time_frame>3 weeks for end of Temocillin Treatment</time_frame>
    <description>The acquisition of resistance will be monitored in the central laboratory and is defined as an increase in MIC of at least 4 dilutions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Temocillin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.&#xD;
Total antibiotic treatment between 10 and 14 days according to local guidelines (up to 21 days in immunosuppressed patients).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temocillin</intervention_name>
    <description>Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.</description>
    <arm_group_label>Temocillin</arm_group_label>
    <other_name>NEGABAN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of at least 18 year old&#xD;
&#xD;
          -  Patient benefits from social security&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  A urinary tract infection due to a confirmed ESBL producing strain (detected by the&#xD;
             use of a rapid diagnostic test applied on the urine) requiring parenteral&#xD;
             antimicrobial therapy&#xD;
&#xD;
          -  Hospitalized patient&#xD;
&#xD;
          -  For women able to procreate: Use of an acceptable method of birth control throughout&#xD;
             the study. Acceptable methods of birth control are: oral contraceptives, intrauterine&#xD;
             device (IUD), diaphragm with spermicide and condom. (All forms of hormonal&#xD;
             contraception are acceptable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient infected with a bacteria which is not an ESBL-producing or AmpC hyperproducing&#xD;
             Enterobacteriaceae&#xD;
&#xD;
          -  Patients infected with a strain sensible to both fluoroquinolones and&#xD;
             trimethoprim/sulfamethoxazole&#xD;
&#xD;
          -  Patients infected with a strain resistant to temocillin&#xD;
&#xD;
          -  Hospital-acquired urinary tract infection (defined as a urinary infection that&#xD;
             occurred at least 48h post admission in the hospital)&#xD;
&#xD;
          -  Patients has received any dose of active antimicrobial therapy (an antibiotic to which&#xD;
             the infecting bacterium is susceptible) in the last 48h (prior to enrolment) except ≤&#xD;
             2 dose of gentamicin.&#xD;
&#xD;
          -  Patients presenting another site of infection than urinary (except onset of&#xD;
             bacteraemia from urinary tract origin) due to Gram negative bacteria.&#xD;
&#xD;
          -  Patients needing concomitant antimicrobial therapy.&#xD;
&#xD;
          -  Septic shock&#xD;
&#xD;
          -  Children (up to 18 years old)&#xD;
&#xD;
          -  Women who is pregnant, breastfeeding, or expecting to conceive at any time during the&#xD;
             study (pregnancy test will be conducted for woman without menopause)&#xD;
&#xD;
          -  Patients with any kind of urinary/bladder catheter (JJ ureteral probe, …)&#xD;
&#xD;
          -  Hypersensitivity to the active substance, to penicillins or to any other type of&#xD;
             beta-lactam agent&#xD;
&#xD;
          -  Chronically dialyzed patients&#xD;
&#xD;
          -  Patients having a creatinine clearance &lt; 30 mL/min&#xD;
&#xD;
          -  Complete obstruction of the urinary tract&#xD;
&#xD;
          -  Perinephretic or intrarenal abscesses&#xD;
&#xD;
          -  Tutorship or curatorship patient&#xD;
&#xD;
          -  Patient unable to give his consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Paul STAHL, PU-PH</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Ajaccio</name>
      <address>
        <city>Ajaccio</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Avicenne Hospital</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Beaujon Hospital</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Martinique</name>
      <address>
        <city>Fort De France</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Bicêtre Hospital</name>
      <address>
        <city>Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Bichat Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - St Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Perpignan</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Pointe à Pitre</name>
      <address>
        <city>Pointe À Pitre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Laterre PF, Wittebole X, Van de Velde S, Muller AE, Mouton JW, Carryn S, Tulkens PM, Dugernier T. Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. J Antimicrob Chemother. 2015 Mar;70(3):891-8. doi: 10.1093/jac/dku465. Epub 2014 Nov 27.</citation>
    <PMID>25433006</PMID>
  </reference>
  <reference>
    <citation>Balakrishnan I, Awad-El-Kariem FM, Aali A, Kumari P, Mulla R, Tan B, Brudney D, Ladenheim D, Ghazy A, Khan I, Virgincar N, Iyer S, Carryn S, Van de Velde S. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2011 Nov;66(11):2628-31. doi: 10.1093/jac/dkr317. Epub 2011 Aug 2.</citation>
    <PMID>21810837</PMID>
  </reference>
  <reference>
    <citation>Fournier D, Chirouze C, Leroy J, Cholley P, Talon D, Plésiat P, Bertrand X. Alternatives to carbapenems in ESBL-producing Escherichia coli infections. Med Mal Infect. 2013 Feb;43(2):62-6. doi: 10.1016/j.medmal.2013.01.006. Epub 2013 Feb 19.</citation>
    <PMID>23433608</PMID>
  </reference>
  <reference>
    <citation>Schulze B, Heilmann HD. Treatment of severe infections with temocillin. Clinical and bacteriological evaluation. Drugs. 1985;29 Suppl 5:207-9.</citation>
    <PMID>4029026</PMID>
  </reference>
  <reference>
    <citation>De Jongh R, Hens R, Basma V, Mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother. 2008 Feb;61(2):382-8. Epub 2007 Dec 10.</citation>
    <PMID>18070831</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>November 27, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2016</study_first_posted>
  <last_update_submitted>June 1, 2018</last_update_submitted>
  <last_update_submitted_qc>June 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temocillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

